Barrett's Esophagus

3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

TM
Trio MedicinesUK - London
2 programs
2
YF476Phase 21 trial
YF476Phase 21 trial
Active Trials
NCT01298999CompletedEst. Dec 2017
NCT02597712CompletedEst. Dec 2017
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Endoscopy and pH studyPhase 11 trial
Active Trials
NCT00573911Completed16Est. Jan 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Trio MedicinesYF476
Trio MedicinesYF476
AstraZenecaEndoscopy and pH study

Clinical Trials (3)

Total enrollment: 16 patients across 3 trials

NCT02597712Trio MedicinesYF476

YF476 in Barrett's Esophagus

Start: May 2013Est. completion: Dec 2017
Phase 2Completed
NCT01298999Trio MedicinesYF476

Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus

Start: Jun 2010Est. completion: Dec 2017
Phase 2Completed
NCT00573911AstraZenecaEndoscopy and pH study

Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus

Start: Aug 2007Est. completion: Jan 201116 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space